Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GP120-depleted HIV-1 vaccine

Next Previous
X
Search
Drug Profile

GP120-depleted HIV-1 vaccine

Alternative Names: AG-1661; gp120 depleted HZ321 HIV-1; HIV vaccine - Immune Response; IR-8101; REMUNE; Remune Paediatric; RG-83894

Latest Information Update: 28 Jan 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Salk Institute
  • Developer Immune Response BioPharma
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 30 Oct 2019 Phase I/II for HIV-1 infections (In adolescents, In children)is still ongoing in USA (IM)
  • 30 Oct 2019 Immune Response BioPharma announces intention to submit BLA to US FDA for HIV-1 infections (In infants, In children, In adolescents) in Q1 2020
  • 17 Sep 2018 GP120 depleted HIV-1 vaccine is available on expanded access (Immune Response BioPharma pipeline, September 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top